Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Allogene Therapeutics, Inc. (ALLO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2023 4 Douglas Earl Martin (GENERAL COUNSEL) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Granted 108,958 shares @ $0
Granted 326,876 shares @ $0
Granted 960,854 options to buy @ $4.13, valued at $4M
08/17/2023 3 Douglas Earl Martin (GENERAL COUNSEL) has filed a Form 3 on Allogene Therapeutics, Inc.
08/14/2023 4 CHEN YINLIN JACK (SVP, Finance) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Granted 11,401 shares @ $0
Granted 39,160 options to buy @ $4.21, valued at $164.9k
08/14/2023 3 CHEN YINLIN JACK (SVP, Finance) has filed a Form 3 on Allogene Therapeutics, Inc.
08/09/2023 4 Mayo Stephen (Director) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Sold 10,000 shares @ $4.2855, valued at $42.9k
08/07/2023 144 Form 144 - Report of proposed sale of securities:
08/02/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/02/2023 8-K Quarterly results
Docs: "Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update"
07/10/2023 SC 13G FMR LLC reports a 17.1% stake in ALLOGENE THERAPEUTICS INC
06/29/2023 144 Form 144 - Report of proposed sale of securities:
06/15/2023 4 MESSEMER DEBORAH M. (Director) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Granted 74,561 shares @ $0
06/15/2023 4 Barrett Elizabeth A. (Director) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Granted 116,120 options to buy @ $5.7, valued at $661.9k
06/15/2023 4 SATO VICKI L (Director) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Granted 59,649 shares @ $0
Granted 23,224 options to buy @ $5.7, valued at $132.4k
06/15/2023 4 Humer Franz B (Director) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Granted 74,561 shares @ $0
06/15/2023 4 WITTE OWEN N. (Director) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Granted 74,561 shares @ $0
06/12/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 8-K Other Events  Interactive Data
04/26/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/26/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
04/24/2023 ARS Form ARS - Annual Report to Security Holders:
04/24/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/24/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/20/2023 8-K Quarterly results
04/05/2023 4 Smith Lillian (VP, Corporate Counsel) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Granted 56,545 shares @ $0
04/05/2023 3 Smith Lillian (VP, Corporate Counsel) has filed a Form 3 on Allogene Therapeutics, Inc.
03/24/2023 4 MOORE ALISON (Chief Technical Officer) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Granted 558,094 shares @ $0
Granted 432,738 options to buy @ $5.04, valued at $2.2M
03/24/2023 4 SCHMIDT ERIC THOMAS (CFO) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Granted 558,094 shares @ $0
Granted 432,738 options to buy @ $5.04, valued at $2.2M
03/24/2023 4 Roberts Zachary (EVP of R&D) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Granted 148,035 shares @ $0
03/24/2023 4 Belldegrun Arie (Director) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Granted 1,282,976 shares @ $0
Granted 994,800 options to buy @ $5.04, valued at $5M
03/24/2023 4 Chang David D (President and CEO) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Granted 1,924,464 shares @ $0
Granted 1,492,200 options to buy @ $5.04, valued at $7.5M
03/16/2023 4 Chang David D (President and CEO) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Paid exercise price by delivering 22,340 shares @ $5.56, valued at $124.2k
03/16/2023 4 SCHMIDT ERIC THOMAS (CFO) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Paid exercise price by delivering 35,879 shares @ $5.47, valued at $196.3k
03/16/2023 4 MOORE ALISON (Chief Technical Officer) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Paid exercise price by delivering 8,351 shares @ $5.5071, valued at $46k
03/16/2023 4 Bhavnagri Veer (General Counsel) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns: Paid exercise price by delivering 23,628 shares @ $5.67, valued at $134k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy